News | Heart Valve Technology | May 18, 2016

Implantation of Rapid Deployment Aortic Valve Found Durable, Safe and Effective

TRANSFORM Trial shows Edwards Intuity valve system shortens duration of interrupted blood flow and heart stoppage during surgery

RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting

May 18, 2016 — The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic valve replacement (RDAVR) system for patients with severe aortic stenosis. Results of the study were presented at the 96th American Association for Thoracic Surgery (AATS) Annual Meeting,

Investigators showed that more than 96 percent of TRANSFORM patients had survived after one year and only 0.2 percent required reoperation. Cardiac function improved in 73 percent. Compared to conventional treatment, this procedure required significantly less cross-clamp and cardiopulmonary bypass times, even when smaller incisions were used.

The investigational RDAVR system used in the TRANSFORM trial, the Edwards Intuity valve system, was developed to combine the ease-of-use functionality of rapid deployment valve fixation with the proven long-term durability of the Perimount Magna Ease valve. The device tested included new innovations such as a polyester sealing cloth and a balloon-expandable stainless steel frame.

“The Edwards Intuity valve system reduces operative complexity by allowing the valve to be placed using only three guiding sutures,” explained Walter Randolph Chitwood, Jr., M.D., founder of the East Carolina Heart Institute of East Carolina University, Greenville, N.C. “The TRANSFORM clinical trial shows that this device reduces the duration that the heart is stopped. By simplifying the steps to implant the aortic valve, surgeons are able to use smaller, less invasive incisions. This benefits patients by causing less pain and promoting faster recovery.”

The trial was a prospective, nonrandomized, single-arm clinical trial that enrolled patients in 29 medical centers. Enrolled patients were at least 18 years of age and required aortic valve replacement. Of 889 enrolled patients, 839 received an Edwards Intuity. The study evaluated both the first-generation (n=109) and the second-generation Edwards Intuity Elite (n=730). The mean age was 73.5 years; 52.2 percent were categorized as New York Heart Association (NYHA) Class II and 30.5 percent as NYHA Class III heart failure. Some patients also underwent other procedures at the same time, such as coronary artery bypass grafting (28 percent) and atrial ablation (5.5 percent). Three surgical approaches were utilized. Almost 60 percent required full sternotomy, 33 percent required mini upper sternotomy and 8 percent right anterior thoracotomy.

Thirty-day mortality was 0.8 percent, and 96.4 percent were alive at the end of the first year post-surgery. At 30 days, the reoperation rate was 0.2 percent and 0.1 percent required valve removal. Functionally, 73 percent showed improvement in their NYHA heart failure classification, while 23.6 percent were unchanged, and 3.3 percent worsened at one year.

In terms of complications, 3.5 percent experienced thromboembolism and 1.3 percent had major bleeding within 30 days. The investigators observed that the rates of leakage around the valves (1.1 percent with leakage and 0.2 percent with major leakage) were clinically acceptable for this type of procedure. By two years, 90.3 percent of patients had no or trivial leaks and 9.7 percent had mild leakage.

For all three surgical approaches, interruption of the normal circulation to accomplish the aortic replacement was significantly less than required by conventional surgery as reported in the STS Adult Cardiac Surgery Database. For example, for patients undergoing full sternotomy, average time for aortic cross clamping went from 76.4 minutes to 49.3 minutes, and cardiopulmonary bypass time was reduced from 104.2 minutes to 69.2 minutes with INTUITY. Similar time savings were observed in patients who underwent smaller incisions with mini sternotomy.

For more information: www.aats.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init